Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal Hsp90 inhibitor
- Development stage
- Preclinical
- Lead developer
- ZoneOne Pharma
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
The liposomal Hsp90 inhibitor is a preclinical-stage therapeutic candidate being developed by ZoneOne Pharma for the treatment of cancer. The drug consists of a small molecule inhibitor of Heat Shock Protein 90 (Hsp90) encapsulated within a proprietary liposomal delivery system. Hsp90 is a molecular chaperone essential for the folding, stability, and function of numerous 'client' proteins, many of which are oncogenic drivers such as kinases and transcription factors. By inhibiting Hsp90, the drug triggers the degradation of these proteins via the ubiquitin-proteasome pathway, disrupting multiple signaling pathways necessary for tumor cell survival and proliferation. The liposomal formulation is designed to enhance the drug's delivery to tumor tissues through the enhanced permeability and retention (EPR) effect while minimizing systemic toxicities and improving the solubility of the Hsp90 inhibitor payload. The development of this candidate has been supported by a contract from the National Cancer Institute (NCI).
- Other names
- Liposomal Hsp90 Inhibitor
02
Targets
HSP90 (Heat shock protein 90 chaperone complex)
Beyond the preview
Go deeper on liposomal Hsp90 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal Hsp90 inhibitor.